Difference between revisions of "Bupropion-agomelatine"
From Psychiatrienet
| Line 8: | Line 8: | ||
| start = | | start = | ||
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day. | * '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day. | ||
| − | * '''Day 8:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. }} | + | * '''Day 8:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. |
| + | }} | ||
Revision as of 16:10, 2 February 2010
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from bupropion to agomelatine.[1] [2]
Stop bupropion - Before day 1: gradually reduce dosage of bupropion to a maximum of 300 mg/day, when this dosage is > 300 mg/day.
- Day 1: reduce dosage of bupropion to 150 mg/day.
- Day 8: stop administration of bupropion.
Start agomelatine- Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
- Day 8: only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
